News
If you’re benchmarking or experiencing performance problems in your React apps, make sure you’re testing with the minified production build.
Fibralign Sponsors International Research Seminar
Fibralign is hosting the inaugural Lymphedema Summit on January 23- Fibralign is hosting the inaugural Lymphedema Summit on January 23, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” For more details:...
Fibralign Selected as a UCSF Rosenman Institute Innovator
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
UChicago Medicine Enrolling Patients in Lymphbridge™ Clinical Study For Surgical Treatment Of Breast Cancer-Related Lymphedema
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
Fibralign Announces CE Mark Approval for BioBridge®
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
Fibralign Announces Strategic Partnership with Terumo
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...
Fibralign Awarded SBIR Phase IIS from Department of Defense
Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...
Fibralign receives ISO 13485:2016 upgrade certification
Fibralign received Certification Notification on January 21, 2019 from DEKRA Certification B. V. that the Company's management system meets the requirements of EN ISO 13486:2016. This internationally agreed standard sets out the requirements for a quality management...